214 related articles for article (PubMed ID: 12598351)
1. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.
van Wijk FH; Aapro MS; Bolis G; Chevallier B; van der Burg ME; Poveda A; de Oliveira CF; Tumolo S; Scotto di Palumbo V; Piccart M; Franchi M; Zanaboni F; Lacave AJ; Fontanelli R; Favalli G; Zola P; Guastalla JP; Rosso R; Marth C; Nooij M; Presti M; Scarabelli C; Splinter TA; Ploch E; Beex LV; ten Bokkel Huinink W; Forni M; Melpignano M; Blake P; Kerbrat P; Mendiola C; Cervantes A; Goupil A; Harper PG; Madronal C; Namer M; Scarfone G; Stoot JE; Teodorovic I; Coens C; Vergote I; Vermorken JB;
Ann Oncol; 2003 Mar; 14(3):441-8. PubMed ID: 12598351
[TBL] [Abstract][Full Text] [Related]
2. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study.
Thigpen JT; Brady MF; Homesley HD; Malfetano J; DuBeshter B; Burger RA; Liao S
J Clin Oncol; 2004 Oct; 22(19):3902-8. PubMed ID: 15459211
[TBL] [Abstract][Full Text] [Related]
3. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study.
Thigpen JT; Blessing JA; DiSaia PJ; Yordan E; Carson LF; Evers C
J Clin Oncol; 1994 Jul; 12(7):1408-14. PubMed ID: 8021731
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group.
van Wijk FH; Lhommé C; Bolis G; Scotto di Palumbo V; Tumolo S; Nooij M; de Oliveira CF; Vermorken JB;
Eur J Cancer; 2003 Jan; 39(1):78-85. PubMed ID: 12504662
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer.
Wagenaar HC; Pecorelli S; Vergote I; Curran D; Wagener DJ; Kobierska A; Bolis G; Bokkel-Huinink WT; Lacave AJ; Madronal C; Forn M; de Oliveira CF; Mangioni C; Nooij MA; Goupil A; Kerbrat P; Marth CH; Tumolo S; Herben MG; Zanaboni F; Vermorken JB
Eur J Gynaecol Oncol; 2001; 22(3):187-93. PubMed ID: 11501769
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
Gallion HH; Brunetto VL; Cibull M; Lentz SS; Reid G; Soper JT; Burger RA; Andersen W;
J Clin Oncol; 2003 Oct; 21(20):3808-13. PubMed ID: 14551299
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group.
Crino L; Tonato M; Darwish S; Meacci ML; Corgna E; Di Costanzo F; Buzzi F; Fornari G; Santi E; Ballatori E
Cancer Chemother Pharmacol; 1990; 26(1):52-6. PubMed ID: 2157554
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin and vinorelbine in advanced and/or metastatic adenocarcinoma of the endometrium: a new highly active chemotherapeutic regimen.
Gebbia V; Testa A; Borsellino N; Ferrera P; Tirrito M; Palmeri S
Ann Oncol; 2001 Jun; 12(6):767-72. PubMed ID: 11484950
[TBL] [Abstract][Full Text] [Related]
9. Postoperative adjuvant chemotherapy with cisplatin, cyclophosphamide, and anthracycline (doxorubicin, epirubicin, pirarubicin) for endometrial cancer.
Yahata H; Hirakawa T; Fujita T; Ariyoshi K; Sonoda K; Amada S; Kobayashi H; Nakano H
Int J Clin Oncol; 2004 Aug; 9(4):317-21. PubMed ID: 15375709
[TBL] [Abstract][Full Text] [Related]
10. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study.
Fleming GF; Filiaci VL; Bentley RC; Herzog T; Sorosky J; Vaccarello L; Gallion H
Ann Oncol; 2004 Aug; 15(8):1173-8. PubMed ID: 15277255
[TBL] [Abstract][Full Text] [Related]
11. A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.
Ducreux M; Van Cutsem E; Van Laethem JL; Gress TM; Jeziorski K; Rougier P; Wagener T; Anak O; Baron B; Nordlinger B;
Eur J Cancer; 2005 Feb; 41(3):398-403. PubMed ID: 15691639
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
Susumu N; Sagae S; Udagawa Y; Niwa K; Kuramoto H; Satoh S; Kudo R;
Gynecol Oncol; 2008 Jan; 108(1):226-33. PubMed ID: 17996926
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma.
Pierga JY; Diéras V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Scholl SM; Garcia-Giralt E; Pouillart P
Gynecol Oncol; 1997 Aug; 66(2):246-9. PubMed ID: 9264570
[TBL] [Abstract][Full Text] [Related]
14. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Kim NK; Park YS; Heo DS; Suh C; Kim SY; Park KC; Kang YK; Shin DB; Kim HT; Kim HJ
Cancer; 1993 Jun; 71(12):3813-8. PubMed ID: 8508349
[TBL] [Abstract][Full Text] [Related]
15. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.
Norris B; Pritchard KI; James K; Myles J; Bennett K; Marlin S; Skillings J; Findlay B; Vandenberg T; Goss P; Latreille J; Rudinskas L; Lofters W; Trudeau M; Osoba D; Rodgers A
J Clin Oncol; 2000 Jun; 18(12):2385-94. PubMed ID: 10856098
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma.
Hidaka T; Nakamura T; Shima T; Yuki H; Saito S
J Obstet Gynaecol Res; 2006 Jun; 32(3):330-7. PubMed ID: 16764625
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.
Yeo W; Mok TS; Zee B; Leung TW; Lai PB; Lau WY; Koh J; Mo FK; Yu SC; Chan AT; Hui P; Ma B; Lam KC; Ho WM; Wong HT; Tang A; Johnson PJ
J Natl Cancer Inst; 2005 Oct; 97(20):1532-8. PubMed ID: 16234567
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
Comella P; Frasci G; De Cataldis G; Panza N; Cioffi R; Curcio C; Belli M; Bianco A; Ianniello G; Maiorino L; Della Vittoria M; Perchard J; Comella G
Br J Cancer; 1996 Dec; 74(11):1805-11. PubMed ID: 8956797
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.
Volgger B; Zeimet AG; Reinthaller A; Petru E; Schauer C; Klein M; Sevelda-Schwarzgruber U; Bogner G; Wolfram G; Marth C
Int J Gynecol Cancer; 2015 Feb; 25(2):257-62. PubMed ID: 25611899
[TBL] [Abstract][Full Text] [Related]
20. Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
Nagao S; Nishikawa T; Hanaoka T; Kurosaki A; Iwasa N; Hasegawa K; Fujiwara K
Jpn J Clin Oncol; 2014 Nov; 44(11):1040-4. PubMed ID: 25183770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
